PHS
DNTH icon

PFM Health Sciences’s Dianthus Therapeutics DNTH Stock Holding History

PFM Health Sciences’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.8M Sell
121,222
-50,915
-30% -$4.45M 1.01% 36
2026
Q1 		$14.4M Buy
172,137
+72,561
+73% +$4.2M 1.32% 22
2025
Q4 		$4.1M Buy
99,576
+31,736
+47% +$1.23M 0.41% 59
2025
Q3 		$2.67M Buy
+67,840
New +$1.73M 0.21% 65

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

PFM Health Sciences's DNTH Position: Q2 2026 in Review

PFM Health Sciences reduced its Dianthus Therapeutics (DNTH) stake by 30% in Q2 2026, selling an estimated $4.45M and leaving 121,222 shares worth $11.8M. The position accounts for 1.01% of the portfolio, ranked #36.

PFM Health Sciences first reported a position in DNTH in Q3 2025 and has held it in 4 quarters since. The position peaked at $14.4M in Q1 2026. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • PFM Health Sciences held 121,222 shares of Dianthus Therapeutics worth $11.8M as of Q2 2026.
  • PFM Health Sciences sold 50,915 Dianthus Therapeutics shares in Q2 2026, an estimated $4.45M.
  • Dianthus Therapeutics made up 1.01% of PFM Health Sciences's portfolio in Q2 2026, its #36 holding.
  • PFM Health Sciences first reported a position in Dianthus Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • PFM Health Sciences's Dianthus Therapeutics position peaked at $14.4M in Q1 2026.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on PFM Health Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.